Umberto Vitolo, Annalisa Chiappella, Emanuele Angelucci, Giuseppe Rossi, A.M. Liberati, M. G. Cabras, Barbara Botto, Giovannino Ciccone, Gianluca Gaïdano, Lorenzo Falchi, Roberto Freilone, Domenico Novero, Lorella Orsucci, V. Pavone, Enrico Pogliani, Delia Rota‐Scalabrini, Francesca Salvi, Anna Tonso, Alessandra Tucci, Alessandro Levis,
Background We investigated the addition of rituximab to dose-dense and high-dose chemotherapy with autologous stem cell transplantation in patients with untreated poor-prognosis diffuse large B-cell lymphoma.Design and Methods Ninety-four young patients (age, 18–60) with stage III–IV diffuse large B-cell lymphoma at intermediate/high or high risk according to the age-adjusted International Prognostic Index were enrolled into a phase II trial. The treatment was as follows: four courses of bi-weekly ...
Tópico(s): Viral-associated cancers and disorders
2009 - Ferrata Storti Foundation | Haematologica
Marco Ladetto, Chiara Lobetti‐Bodoni, Barbara Mantoan, Manuela Ceccarelli, Carola Boccomini, Elisa Genuardi, Annalisa Chiappella, Luca Baldini, Giuseppe Rossi, Alessandro Pulsoni, Francesco Di Raimondo, Luigi Rigacci, Antonio Pinto, Sara Galimberti, Alessia Bari, Delia Rota‐Scalabrini, Angela Ferrari, Francesco Zaja, Andrea Gallamini, Giorgina Specchia, Pellegrino Musto, Francesca Gaia Rossi, Enrica Gamba, Andrea Evangelista, Umberto Vitolo,
Key Points PCR negativity is a strong outcome predictor after rituximab-intensive immunochemotherapy at multiple posttreatment times. PCR is predictive even when maintenance is delivered, and accumulation of PCR-negative results further reduces the likelihood of relapse.
Tópico(s): CNS Lymphoma Diagnosis and Treatment
2013 - Elsevier BV | Blood
Umberto Vitolo, Annalisa Chiappella, Ercole Brusamolino, Emanuele Angelucci, Giuseppe Rossi, Angelo Michele Carella, Andrea Evangelista, Caterina Stelitano, Monica Balzarotti, Francesco Merli, Gianluca Gaïdano, Vincenzo Pavone, Luigi Rigacci, Francesco Zaja, Nicola Cascavilla, Alfonso Maria D’Arco, Chiara Rusconi, Amalia De Renzo, Graziella Pinotti, Michele Spina, Patrizia Pregno, Eleonora Russo, Manuel Gotti, Alessandra Tucci, Maria Giuseppina Cabras, Stefano Pileri, Alessandro Levis, Maurizio Martelli,
Abstract Abstract 688 Introduction. The prognosis of young DLBCL patients at high risk treated with standard R-CHOP is still rather poor. The role of intensified HDC+ASCT in first line treatment is still a matter of debate in the Rituximab era. The FIL planned a prospective randomized phase III trial with a 2×2 factorial design aimed at investigating the possible benefit of intensification with R-HDC+ASCT after R-dose-dense chemotherapy delivered at two different level of dose (R-CHOP14/R-MegaCHOP14). ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2012 - Elsevier BV | Blood
Barbara Botto, Marilena Bellò, Giulia Benevolo, Maria Giuseppina Cabras, Claudia Castellino, Annalisa Chiappella, Giuseppe Fioritoni, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Giovanni Bisi, Umberto Vitolo, Eugenio Gallo,
Abstract Introduction: The addition of antibody monoclonal anti CD20 Rituximab to CHOP chemotherapy has resulted in improved CR, progression free survival and overall survival rates for patients affected by diffuse large B cell lymphoma. Recently, RIT with Zevalin has been shown effective in the treatment of relapsed refractory elderly DLBCL. We report the results of a study to evaluate the efficacy and safety of Zevalin in relapsed or chemoresistant aggressive lymphoma previously treated with Rituximab. ...
Tópico(s): Glycosylation and Glycoproteins Research
2007 - Elsevier BV | Blood
Sabino Ciavarella, M.C. Vegliante, Marco Fabbri, Simona De Summa, Federica Melle, Giovanna Motta, Vincenzo De Iuliis, Giuseppina Opinto, Anna Enjuanes, S Rega, Alessandro Gulino, Claudio Agostinelli, Anna Scattone, Stefania Tommasi, Anita Mangia, F. Mele, G. Simone, Alfredo Zito, Giuseppe Ingravallo, Umberto Vitolo, Annalisa Chiappella, Corrado Tarella, Alessandro M. Gianni, Alessandro Rambaldi, Pier Luigi Zinzani, Beatrice Casadei, Enrico Derenzini, Giacomo Loseto, Alessandro Pileri, Valentina Tabanelli, Sonia Fiori, Alfredo Rivas‐Delgado, A. López-Guillermo, Tiziana Venesio, Anna Sapino, Elı́as Campo, Claudio Tripodo, Attilio Guarini, Stefano Pileri,
Ann Oncol 2018; 29: 2363–2370 (doi: 10.1093/annonc/mdy450) The affiliations of authors T. Venesio and A. Sapino were originally incorrect. These have now been corrected as per the author listing above. Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissueAnnals of OncologyVol. 29Issue 12PreviewGene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large ...
Tópico(s): Sarcoma Diagnosis and Treatment
2019 - Elsevier BV | Annals of Oncology
Sabino Ciavarella, M.C. Vegliante, Marco Fabbri, Simona De Summa, Federica Melle, Giovanna Motta, Vincenzo De Iuliis, Giuseppina Opinto, Anna Enjuanes, S Rega, Alessandro Gulino, Claudio Agostinelli, Anna Scattone, Stefania Tommasi, Anita Mangia, F. Mele, G. Simone, Alfredo Zito, Giuseppe Ingravallo, Umberto Vitolo, Annalisa Chiappella, Corrado Tarella, Alessandro M. Gianni, Alessandro Rambaldi, Pier Luigi Zinzani, Beatrice Casadei, Enrico Derenzini, Giacomo Loseto, Alessandro Pileri, Valentina Tabanelli, Sonia Fiori, Alfredo Rivas‐Delgado, Armando López‐Guillermo, Tiziana Venesio, Anna Sapino, Elı́as Campo, Claudio Tripodo, Attilio Guarini, Stefano Pileri,
BackgroundGene expression profiling (GEP) studies recognized a prognostic role for tumor microenvironment (TME) in diffuse large B-cell lymphoma (DLBCL), but the routinely adoption of prognostic stromal signatures remains limited.Patients and methodsHere, we applied the computational method CIBERSORT to generate a 1028-gene matrix incorporating signatures of 17 immune and stromal cytotypes. Then, we carried out a deconvolution on publicly available GEP data of 482 untreated DLBCLs to reveal associations ...
Tópico(s): Molecular Biology Techniques and Applications
2018 - Elsevier BV | Annals of Oncology
Annalisa Chiappella, Maurizio Martelli, Emanuele Angelucci, Ercole Brusamolino, Andrea Evangelista, Angelo Michele Carella, Caterina Stelitano, Giuseppe Rossi, Monica Balzarotti, Francesco Merli, Gianluca Gaïdano, Vincenzo Pavone, Luigi Rigacci, Francesco Zaja, Alfonso Maria D’Arco, Nicola Cascavilla, Eleonora Russo, Alessia Castellino, Manuel Gotti, Angela Giovanna Congiu, Maria Giuseppina Cabras, Alessandra Tucci, Claudio Agostinelli, Giovannino Ciccone, Stefano Pileri, Umberto Vitolo,
Background The prognosis of young patients with diffuse large B-cell lymphoma at high risk (age-adjusted International Prognostic Index [aa-IPI] score 2 or 3) treated with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) is poor. The aim of this study was to investigate the possible benefit of intensification with high-dose chemotherapy and autologous stem-cell transplantation as part of first-line treatment in these patients. Methods We did a multicentre, open-label, ...
Tópico(s): CAR-T cell therapy research
2017 - Elsevier BV | The Lancet Oncology
Anna Dodero, Anna Guidetti, Fabrizio Marino, Alessandra Tucci, Francesco Barretta, Alessandro Re, Monica Balzarotti, Cristiana Carniti, Chiara Monfrini, Annalisa Chiappella, Antonello D. Cabras, Fabio Facchetti, Martina Pennisi, Daoud Rahal, Valentina Monti, Liliana Devizzi, Rosalba Miceli, Federica Cocito, Lucia Farina, Francesca Ricci, Giuseppe Rossi, Carmelo Carlo‐Stella, Paolo Corradini,
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, including one-third of cases overexpressing MYC and BCL2 proteins (double expressor lymphoma, DEL) and 5-10% of patients with chromosomal rearrangements of MYC, BCL2 and/or BCL-6 (double/triple-hit lymphomas, DH/TH). TP53 mutations are detected in 20- 25% of DEL. We report the efficacy of dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in a series of 122 consecutive patients, including DEL (n=81, 66%), DEL-MYC (n=9, 7%), DEL-BCL2 (n=13, 11%), ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2021 - Ferrata Storti Foundation | Haematologica
Annalisa Arcari, Annalisa Chiappella, Michele Spina, Luca Zanlari, Patrizia Bernuzzi, Vanessa Valenti, Monica Tani, Roberto Marasca, Maria Giuseppina Cabras, Renato Zambello, Alberto Santagostino, Fiorella Ilariucci, Giuseppe Carli, Pellegrino Musto, Paolo Savini, Dario Marino, Francesco Ghio, Massimo Gentile, Maria Christina Cox, Daniele Vallisa,
Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R–B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age ...
Tópico(s): Viral-associated cancers and disorders
2015 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Francesco Merli, Stefano Luminari, Giuseppe Rossi, Caterina Mammi, Luigi Marcheselli, Alessandra Tucci, Fiorella Ilariucci, Annalisa Chiappella, Maurizio Musso, Alice Di Rocco, Caterina Stelitano, Isabel Alvarez, Luca Baldini, Patrizio Mazza, Flavia Salvi, Annalisa Arcari, Alberto Fragasso, Paolo G. Gobbi, Anna Marina Liberati, Massimo Federico,
We conducted a prospective study to compare epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab (R-miniCEOP) with cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (R-CHOP) for the treatment of "fit" elderly patients with diffuse large B-cell lymphoma (DLBCL). Patients over the age of 65 with stage II-IV DLBCL were screened with a comprehensive geriatric assessment. Patients were randomized to receive six courses of R-miniCEOP (n = 114) or R-CHOP (n = 110). Overall, the ...
Tópico(s): Viral-associated cancers and disorders
2011 - Taylor & Francis | Leukemia & lymphoma/Leukemia and lymphoma
Umberto Vitolo, Marco Ladetto, Carola Boccomini, Andrea Evangelista, Enrica Gamba, Eleonora Russo, Alessandra Tucci, Annalisa Chiarenza, Antonio Pinto, Amalia De Renzo, Francesco Zaja, Andrea Gallamini, Alessia Bari, Isabel Alvarez, Elisa Bernocco, Mario Petrini, Guido Parvis, Benedetta Puccini, Paolo Corradini, Tommasina Perrone, Sharon Supekar, Annalisa Chiappella, Barbara Botto, Barbara Mantoan, Federico De Angelis, Luca Baldini, Giuseppe Rossi,
Abstract Abstract 777 Introduction. Fludarabine containing regimens are effective in FL; the role of Rituximab (R) maintenance has been established recently. Aim of the study was to investigate efficacy and safety of R-maintenance vs. observation in elderly FL patients who respond to a brief chemo-immunotherapy with four courses of R-FND + four doses of Rituximab as consolidation. Methods. From January 2004 to December 2007, elderly patients (age 60–75) with untreated advanced stage FL who required ...
Tópico(s): Viral-associated cancers and disorders
2011 - Elsevier BV | Blood
Umberto Vitolo, Marco Ladetto, Carola Boccomini, Luca Baldini, Federico De Angelis, Alessandra Tucci, Barbara Botto, Annalisa Chiappella, Annalisa Chiarenza, Antonio Pinto, Amalia De Renzo, Francesco Zaja, Claudia Castellino, Alessia Bari, Maria Isabel Alvarez De Celis, Andrea Evangelista, Guido Parvis, Enrica Gamba, Chiara Lobetti‐Bodoni, Giovannino Ciccone, Giuseppe Rossi,
Purpose To evaluate the efficacy of rituximab maintenance in 60- to 75-year-old patients with advanced follicular lymphoma responding to brief first-line chemoimmunotherapy followed by rituximab consolidation. Patients and Methods A total of 234 treatment-naive 60- to 75-year-old patients began chemoimmunotherapy with four monthly courses of rituximab, fludarabine, mitoxantrone, and dexamethasone (R-FND) followed by four weekly cycles of rituximab consolidation. Of these, 210 patients completed the ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2013 - Lippincott Williams & Wilkins | Journal of Clinical Oncology
Annalisa Chiappella, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Giovannino Ciccone, Flavia Salvi, Emanuele Angelucci, Barbara Botto, Antonella Darbesio, Roberto Freilone, Lorella Orsucci, Vincenzo Pavone, Enrico Maria Pogliani, Umberto Ricardi, Delia Rota‐Scalabrini, Anna Tonso, Alessandra Tucci, Eugenio Gallo, Umberto Vitolo,
Abstract Introduction: The addition of R to dose-dense chemotherapy CHOP and to high-dose chemotherapy seems to improve the outcome of advanced stage DLBCL. Patients and methods: From August 2000 to September 2006, 120 previously untreated patients (pts) <61 years affected by aggressive DLBCL were enrolled into 12 GIMURELL centers. Inclusion criteria were: advanced stage II, III-IV with age-adjusted (aa)-IPI score 2–3 or BM involvement (any aa-IPI score), viral markers negativity. Treatment plan ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2007 - Elsevier BV | Blood
Annalisa Chiappella, Alessandra Tucci, Alessia Castellino, Vincenzo Pavone, Ileana Baldi, A Carella, L. Orsucci, Manuela Zanni, Francesca Salvi, Anna Marina Liberati, Gianluca Gaïdano, Chiara Bottelli, B. Rossini, Sonia Perticone, P. De Masi, Marco Ladetto, Giovannino Ciccone, Antonio Palumbo, Giuseppe Rossi, Umberto Vitolo,
Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse. Lenalidomide alone or in combination with rituximab has been shown to be active in relapsed/refractory aggressive lymphomas. In this phase I study we determined the maximum tolerated dose of lenalidomide plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone in untreated, ...
Tópico(s): Multiple Myeloma Research and Treatments
2013 - Ferrata Storti Foundation | Haematologica
Marco Ladetto, Simone Ferrero, Andrea Evangelista, Michael Mian, Alice Di Rocco, Angela Coggi, Giuseppe Rossi, Alessandro Re, Vittorio Stefoni, Federica Cavallo, Annalisa Chiappella, Armando Santoro, Chiara Rusconi, María Gomes da Silva, Manuel Gotti, Anna Lia Molinari, Filippo Ballerini, Andrés J.M. Ferreri, Alberto Bosi, Franco Narni, Caterina Stelitano, Alberto Zamò, Giovannino Ciccone, Umberto Vitolo, Maurizio Martelli, Sergio Cortelazzo,
Abstract Background. Ara-c based chemo-immunotherapy followed by autologous stem cell transplantation (ASCT) is the most effective approach in young mantle cell lymphoma (MCL) patients, though few if any patients are cured. Recent data indicate that subsequent Rituximab maintenance (RM) prolongs PFS and OS (Le Gouill NEJM 2017). Lenalidomide is an oral agent effective in MCL, considered suitable for prolonged maintenance programs, but has never been tested in this setting. The FIL MCL0208 trial (NCT02354313) ...
Tópico(s): Lung Cancer Treatments and Mutations
2018 - Elsevier BV | Blood
Umberto Vitolo, Emanuele Zucca, Maurizio Martelli, Annalisa Chiappella, Ileana Baldi, Monica Balzarotti, Annarita Conconi, Henry Gómez, Armando López‐Guillermo, Giovanni Martinelli, Lorella Orsucci, Vincenzo Pavone, Giuseppe Rossi, Sergio Storti, Mary Gospodarowicz, Franco Cavalli, Andreas H. Sarris,
Abstract Introduction: Diffuse large B-cell lymphoma (DLBCL) of the testis (PTL) is a rare presentation of extranodal lymphoma at poor prognosis with a 5-yr overall survival of 40-55%. Contralateral testis, CNS and extranodal sites relapses are the main cause of failures. IELSG 10 study is a prospective phase II international trial for patients with stage I or II PTL and was designed to define a standard treatment for PTL. It aims to evaluate efficacy and toxicity of a combined treatment of R-CHOP, ...
Tópico(s): Testicular diseases and treatments
2006 - Elsevier BV | Blood
Umberto Vitolo, Maria Giuseppina Cabras, Giuseppe Rossi, Anna Marina Liberati, Annalisa Chiappella, Alessandro Levis, Vincenzo Pavone, Emanuele Angelucci, Barbara Botto, Giovannino Ciccone, Roberto Freilone, Gianluca Gaïdano, Domenico Novero, Isabella Palumbo, Enrico Maria Pogliani, Patrizia Pregno, Delia Rota Scalabrini, Flavia Salvi, Anna Tonso, Alessandra Tucci, Eugenio Gallo,
Abstract Introduction: the efficacy of Rituximab (R) with standard chemotherapy in DLBCL is well known. We investigated efficacy and safety of Rituximab as adjuvant to dose-dense and HDC as part of first line treatment in untreated pts with aa-IPI at Intermediate-High (IH) or High (H) risk with DLBCL. Patients and methods: 77 previously untreated pts <61 years with DLBCL, stage III–IV at aaIPI IH or H risk were enrolled into R-HDC trial (study group; January 2001–December 2004). Treatment consisted in ...
Tópico(s): Acute Lymphoblastic Leukemia research
2006 - Elsevier BV | Blood
Umberto Vitolo, Annalisa Chiappella, Ercole Brusamolino, Emanuele Angelucci, Giuseppe Rossi, Angelo Michele Carella, Andrea Evangelista, Caterina Stelitano, Monica Balzarotti, Francesco Merli, Gianluca Gaïdano, Manuel Gotti, Vincenzo Pavone, Luigi Rigacci, Francesco Zaja, Chiara Rusconi, Amalia De Renzo, Graziella Pinotti, Michele Pizzuti, Michele Spina, Maria Cantonetti, Giorgina Specchia, Patrizia Pregno, Eleonora Russo, Alessandra Tucci, Maria Giuseppina Cabras, Stefano Pileri, Alessandro Levis, Maurizio Martelli,
Abstract Introduction The role of bone marrow (BM) involvement as prognostic factor in untreated young patients with diffuse large B-cell lymphoma at poor prognosis is still a matter of debate. Recent data showed an adverse prognostic role of BM involvement in DLBCL including patients both at low and high IPI score (Sehn L et al, J Clin Oncol 2011). On this basis, FIL analyzed the impact of BM involvement in the prospective randomized phase III trial DLCL04 (Vitolo U et al, Blood, ASH annual Meeting ...
Tópico(s): Acute Lymphoblastic Leukemia research
2013 - Elsevier BV | Blood
Umberto Vitolo, Annalisa Chiappella, Silvia Franceschetti, Angelo Michele Carella, Ileana Baldi, Giorgio Inghirami, Michele Spina, Vincenzo Pavone, Marco Ladetto, Anna Marina Liberati, Anna Lia Molinari, Pier Luigi Zinzani, Flavia Salvi, Pier Paolo Fattori, Alfonso Zaccaria, Martin Dreyling, Barbara Botto, Alessia Castellino, Angela Giovanna Congiu, Marcello Gaudiano, Manuela Zanni, Giovannino Ciccone, Gianluca Gaïdano, Giuseppe Rossi,
Background Up to 40% of elderly patients with untreated diffuse large B-cell lymphoma (DLBCL) given a regimen of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) relapse or develop refractory disease. Lenalidomide has high activity in relapsed or refractory aggressive B-cell lymphomas. In phase 2 of the REAL07 trial, we aimed to establish the safety and efficacy of the combination of lenalidomide and R-CHOP21 in elderly patients with untreated DLBCL. ...
Tópico(s): Chronic Lymphocytic Leukemia Research
2014 - Elsevier BV | The Lancet Oncology
Umberto Vitolo, Annalisa Chiappella, Angelo Michele Carella, Ileana Baldi, Giovannino Ciccone, Angela Giovanna Congiu, Gianluca Gaïdano, Pasqualina De Masi, Marco Ladetto, Alessandro Levis, Anna Marina Liberati, Lorella Orsucci, Vincenzo Pavone, Sonia Perticone, Alessandra Tucci, Manuela Zanni, Giuseppe Rossi,
Tópico(s): Acute Lymphoblastic Leukemia research
2010 - Elsevier BV | Blood
Francesco Merli, Stefano Luminari, Giuseppe Rossi, Caterina Mammi, Luigi Marcheselli, Isabel Alvarez, Alessandra Tucci, Caterina Stelitano, Fiorella Ilariucci, Maurizio Musso, Luca Baldini, Alberto Fragasso, Annalisa Chiappella, Massimo Federico,
Abstract Abstract 1771 Introduction: There are currently no validated methods to prospectively identify elderly patients with Diffuse Large B-cell Lymphoma (B-DLCL) fit enough to receive full-dose treatment. CGA is a multidisciplinary comprehensive evaluation of an old individual's functional status, comorbid medical conditions, psychological state, social support, nutritional status and a review of the patient's medications. Recently CGA has been proposed as an objective tool for supporting medical ...
Tópico(s): Multiple and Secondary Primary Cancers
2010 - Elsevier BV | Blood
Annalisa Arcari, Annalisa Chiappella, Vanessa Valenti, Luca Zanlari, Monica Tani, Roberto Marasca, Maria Giuseppina Cabras, Michele Spina, Alberto Santagostino, Fiorella Ilariucci, Giuseppe Carli, Pellegrino Musto, Paolo Savini, Dario Marino, Francesco Ghio, Massimo Gentile, Maria Christina Cox, Roberta Della Seta, Daniele Vallisa,
Abstract Background: Diffuse large B-cell lymphoma (DLBCL) relapsed or refractory after chemoimmunotherapy have dismal prognosis; the standard salvage treatment is Rituximab plus high dose chemotherapy with autologous stem cell transplantation (R-HDC). However, no standardized treatment is available for patients not eligible for R-HDC because of age and/or comorbidity. The combination Rituximab plus Bendamustine (R-B) has shown to be non-inferior and with a favorable toxicity profile compared to R- ...
Tópico(s): CAR-T cell therapy research
2014 - Elsevier BV | Blood
Barbara Botto, Marilena Bellò, Annalisa Chiappella, Roberto Passera, Giulia Benevolo, Carola Boccomini, Maria Giuseppina Cabras, Claudia Castellino, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Maurizio Martelli, Lorella Orsucci, Patrizia Pregno, Paola Scapoli, Anna Tonso, Umberto Ricardi, Giovanni Bisi, Umberto Vitolo,
Abstract Introduction: The addition of antibody monoclonal anti CD20 Rituximab to CHOP chemotherapy resulted in improved CR, progression free survival and overall survival rates for patients with diffuse large B cell lymphoma (DLBCL). RIT with Zevalin, as single agent, has been shown to be effective in the treatment of relapsed refractory elderly DLBCL, namely in Rituximab naïve patients. However, in patients pretreated with Rituximab the reported response rate was lower. The aim of this study was ...
Tópico(s): Glycosylation and Glycoproteins Research
2008 - Elsevier BV | Blood
Umberto Vitolo, Marco Ladetto, Carola Boccomini, Enrica Gamba, Isabel Alvarez, Luca Baldini, Annalisa Chiappella, Paolo Corradini, Amalia De Renzo, Francesco Di Raimondo, Andrea Evangelista, Andrea Gallamini, Attilio Guarini, Giuseppe Leone, Anna Marina Liberati, Barbara Mantoan, Maurizio Martelli, Lorella Orsucci, Guido Parvis, Mario Petrini, Antonio Pinto, Enrico Pogliani, Samantha Pozzi, Alessandro Pulsoni, Luigi Rigacci, Corrado Tarella, Alessandra Tucci, Francesco Zaja, Eugenio Gallo,
Abstract Introduction: we investigated efficacy and safety of a brief chemo-immunotherapy R-FND with R consolidation followed by randomization between R maintenance or observation in a study specifically devised for elderly. Material and methods: From January 2004 to December 2007, 235 pts (age 60–75) with untreated advanced stage FL were enrolled into 33 IIL centres and written informed consent was obtained. Treatment plan was: 4 courses of R-FND (375 mg/m2 Rituximab on day 0, 25 mg/m2 fludarabine ...
Tópico(s): Acute Lymphoblastic Leukemia research
2008 - Elsevier BV | Blood
Umberto Vitolo, Giuseppe Rossi, Maria Giuseppina Cabras, Anna Marina Liberati, Annalisa Chiappella, Alessandro Levis, Enzo Pavone, Emanuele Angelucci, Barbara Botto, Manuela Ceccarelli, Roberto Freilone, Gianluca Gaïdano, Domenico Novero, Lorella Orsucci, Isabella Palumbo, Enrico Pogliani, Delia Rota Scalabrini, Flavia Salvi, Anna Tonso, Alessandra Tucci, Eugenio Gallo,
Abstract Introduction: We investigated efficacy and safety of adding Rituximab (R) to induction and intensified HDC as part of first line treatment in pts with aa-IPI at Intermediate-High (IH) or High (H) risk with B-DLCL at diagnosis. We compared two groups of similar pts enrolled in two consecutive non-randomized phase II clinical trials with up-front HDC and ASCT with or without R with identical inclusion criteria conducted by GIMURELL. Patients and methods: 118 previously untreated pts <61 years ...
Tópico(s): Acute Lymphoblastic Leukemia research
2005 - Elsevier BV | Blood
Annalisa Chiappella, Silvia Franceschetti, Alessia Castellino, Angelo Michele Carella, Ileana Baldi, Manuela Zanni, Anna Marina Liberati, Michele Spina, Chiara Bottelli, Vincenzo Pavone, Anna Lia Molinari, Pier Luigi Zinzani, Flavia Salvi, Pier Paolo Fattori, Alfonso Zaccaria, Barbara Botto, Angela Giovanna Congiu, Marco Ladetto, Martin Dreyling, Gianluca Gaïdano, Giuseppe Rossi, Umberto Vitolo,
Abstract Abstract 903 Introduction. R-CHOP21 is the standard treatment for untreated elderly DLBCL, however up to 40% of patients fail. There is a need to improve the efficacy of R-CHOP21; an option may be the addition of novel drugs in first line induction therapy. Lenalidomide has a complex mechanism of action as immunemodulation, antiangiogenesis, restoration of immunesynapses and direct antitumor effects. Lenalidomide monotherapy exhibits significant activity in patients with relapsed aggressive ...
Tópico(s): Acute Lymphoblastic Leukemia research
2012 - Elsevier BV | Blood
Annalisa Chiappella, Claudio Agostinelli, Maurizio Martelli, Simona Righi, Andrea Evangelista, Emanuele Angelucci, Monica Balzarotti, Angelo Michele Carella, Manuel Gotti, Domenico Novero, Giuseppe Rossi, Caterina Stelitano, Marco Ladetto, Gianluca Gaïdano, Stefano Pileri, Umberto Vitolo,
Abstract Background. The prognostic role of cell of origin profile (COO) assessed by immunohistochemistry (IHC) is controversial in Rituximab era. FIL conducted a phase III randomized trial aimed at investigating the benefit of intensification with high dose therapy plus autotransplant compared to R-dose-dense therapy as first line in young DLBCL at poor risk (aa-IPI 2-3). Clinical results were reported (Vitolo, ASH 2012). The aim of BIO-DLCL04 was to correlate the biological markers with PFS. Patients ...
Tópico(s): Mycobacterium research and diagnosis
2015 - Elsevier BV | Blood
Luigi Rigacci, Patrizia Pregno, Benedetta Puccini, Andrea Evangelista, Annalisa Chiappella, Gianluca Gaïdano, Luca Nassi, Monica Balzarotti, Francesco Merli, Amalia De Renzo, Alessandro Levis, Michele Spina, Vincenzo Pavone, Roberto Freilone, Stefano Luminari, Giuseppe Rossi, Caterina Stelitano, Angelo Michele Carella, Alfonso Maria D’Arco, Pellegrino Musto, Alberto Bosi, Umberto Vitolo,
Abstract Introduction The role of interim-PET (i-PET), after two cycles of chemotherapy, in advanced stage Hodgkin's lymphoma is well defined; the same role in diffuse large B cell lymphoma (DLBCL) is still controversial. The Fondazione Italiana Linfomi planned a prospective randomized phase III trial, addressed to young poor prognosis DLBCL patients at the diagnosis, with a 2x2 factorial design aimed at investigating the possible benefit of intensification with R-HDC+ASCT after R-dose-dense chemotherapy ...
Tópico(s): Radiopharmaceutical Chemistry and Applications
2013 - Elsevier BV | Blood
Annalisa Chiappella, Maria Giuseppina Cabras, Anna Marina Liberati, Chiara Bottelli, Giovannino Ciccone, Emanuele Angelucci, Luca Baldini, Barbara Botto, Nicola Cascavilla, Sergio Cortelazzo, Pasqualina De Masi, Lorenzo Falchi, Giuseppe Fioritoni, Chiara Frairia, Roberto Freilone, Alessandro Levis, Lorella Orsucci, Guido Parvis, Enrico Maria Pogliani, Delia Rota‐Scalabrini, Flavia Salvi, Giorgina Specchia, Anna Tonso, Alessandra Tucci, Umberto Vitolo,
Abstract Abstract 2316 Poster Board II-293 Introduction: DLBCL at diagnosis with an intermediate/high or high-risk score according to age-adjusted International Prognostic Index (aa-IPI) had a dismal prognosis. High-dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) was showed an effective salvage treatment for chemo-sensitive relapsed patients, but conflicting results were observed as first line treatment in randomized trials. The addition of Rituximab to standard chemotherapy ...
Tópico(s): Acute Lymphoblastic Leukemia research
2009 - Elsevier BV | Blood
Annalisa Chiappella, Silvia Franceschetti, Alessia Castellino, Angelo Michele Carella, Ileana Baldi, Manuela Zanni, Anna Marina Liberati, Michele Spina, Alessandra Tucci, Vincenzo Pavone, Anna Lia Molinari, Pier Luigi Zinzani, Flavia Salvi, Marcello Gaudiano, Pier Paolo Fattori, Alfonso Zaccaria, Barbara Botto, Angela Giovanna Congiu, Giovannino Ciccone, Marco Ladetto, Martin Dreyling, Gianluca Gaïdano, Giorgio Inghirami, Giuseppe Rossi, Umberto Vitolo,
Tópico(s): Acute Lymphoblastic Leukemia research
2013 - Elsevier BV | Blood